Houlihan Lokey Advises Grünenthal

Houlihan Lokey is pleased to announce that Grünenthal GmbH (Grünenthal) has successfully raised a €200 million medium-term bridge facility. The proceeds are expected to be used for the agreed acquisition of Nebido™, a well-known brand for the treatment of testosterone deficiency from Bayer.

Grünenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, it has a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Its purpose is to change lives for the better—and innovation is its passion. Grünenthal focuses all of its activities and efforts on working towards its vision of a world free from pain. Grünenthal is headquartered in Aachen, Germany, and has affiliates in 28 countries across Europe, Latin America, and the US. Its products are available in more than 100 countries. In 2021, Grünenthal employed approximately 4,500 people and achieved standalone sales and EBITDA of approximately €1.5 billion and €370 million, respectively.

Houlihan Lokey served as the exclusive financial advisor to Grünenthal on this transaction.